Edition:
United Kingdom

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

8.19USD
23 Feb 2018
Change (% chg)

$0.07 (+0.86%)
Prev Close
$8.12
Open
$8.12
Day's High
$8.20
Day's Low
$8.12
Volume
3,110
Avg. Vol
54,226
52-wk High
$8.58
52-wk Low
$4.60

Select another date:

Wed, Feb 7 2018

BRIEF-Sinovac Provides Update On Going Private Transaction

* SINOVAC BIOTECH - EXPECTS TO FILE AMENDED GOING-PRIVATE STATEMENT, INCLUDING A DEFINITIVE PROXY STATEMENT AS AN EXHIBIT, WITH U.S. SEC IN DUE COURSE Source text for Eikon: Further company coverage:

BRIEF-Sinovac Biotech Receives Positive Decision On Hepatitis A Vaccine From WHO

* SINOVAC BIOTECH RECEIVES POSITIVE DECISION ON ITS HEPATITIS A VACCINE FROM WORLD HEALTH ORGANIZATION

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​ Source text for Eikon: Further company coverage:

BRIEF-Sinovac reports Q4 earnings per share $0.08

* Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results

BRIEF-Sinovac Biotech receives delisting determination letter from Nasdaq

* Sinovac Biotech announces receipt of delisting determination letter from Nasdaq Source text for Eikon: Further company coverage:

BRIEF-Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share

* Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share

BRIEF-Sinovac Biotech preliminary phase III data shows Varicella vaccine was 87.1 pct efficacious against Chickenpox ​

* Sinovac reports preliminary top-line results from phase III clinical trial for Varicella vaccine candidate against Chickenpox

Select another date: